Aging with HIV: multimorbidity and polypharmacy burden
AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, cilt.37, sa.11, ss.1894-1904, 2025 (SSCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 37 Sayı: 11
- Basım Tarihi: 2025
- Doi Numarası: 10.1080/09540121.2025.2570402
- Dergi Adı: AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
- Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus, BIOSIS, CINAHL, Educational research abstracts (ERA), EMBASE, Gender Studies Database, MEDLINE, Psycinfo, Public Affairs Index, Violence & Abuse Abstracts
- Sayfa Sayıları: ss.1894-1904
- Anahtar Kelimeler: Multimorbidity, Polypharmacy, HIV and aging, Drug-drug interactions, Non-communicable diseases, Older adults living with HIV
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: Aging people living with HIV (PLWH) are at higher risk of multimorbidity and polypharmacy, complicating care. Objective: To assess the prevalence and risk factors of multimorbidity and polypharmacy in elderly PLWH on antiretroviral therapy (ART). Method: In this cross-sectional study, PLWH aged ≥50 were compared with age- and sex-matched people without HIV. Logistic regression was used to identify predictors of polypharmacy. Results: Multimorbidity (≥2 chronic conditions) was seen in 29% of PLWH and 22% of controls. Osteoporosis (9.5% vs. 2.3%) and psychiatric disorders (9.5% vs. 2.8%) were significantly more common in PLWH (p < 0.001). Polypharmacy (≥5 non-ART medications) was more frequent in PLWH (20.4% vs. 11.8%, p = 0.014). In multivariable analysis, being in the PLWH group (aOR 2.41), increasing age (aOR per 1-year 1.05), and having no formal education (aOR 4.59) were independent predictors of polypharmacy. Potential drug–drug interactions were present in 19.4% of PLWH and were present in those with polypharmacy (33% vs. 16%, p < 0.001). Conclusion: Older PLWH experience greater multimorbidity and polypharmacy than people without HIV. Tailored strategies–such as medication review, drug interaction monitoring, and preventive care–are essential to optimize outcomes in this growing and vulnerable population.